Detecting Pharmacy Fraud: Is Your Brand’s Co-Pay Program Protected?

February 12, 2019

The incidences of pharmacy fraud involving pharmaceutical manufacturers’ co-pay card programs are on the rise. In this white paper, TrialCard discusses the steps it has taken to expand its Pharmacy Fraud Monitoring service, which identifies fraud and greatly reduces the reimbursement funds that make it back to the pharmacies in question. This approach has delivered proven results to TrialCard’s pharmaceutical clients and has saved brands valuable reimbursement dollars that otherwise would have been lost.

Spotlight

Nesher Pharmaceuticals (USA) LLC

Nesher Pharmaceuticals (USA) LLC, a generic pharmaceutical manufacturer located in St. Louis, MO, is a subsidiary of Zydus Pharmaceuticals (USA) Inc. Our business is redefining the standards for pharmaceutical performance.

OTHER WHITEPAPERS
news image

2020 Prescription Drug List

whitePaper | April 7, 2020

The information in this document is designed to help you understand the prescription drug benefits offered under this plan and to compare these benefits to those offered by other plans. Information contained in this summary is designed to help you compare both the value and scope offormulary benefits.

Read More
news image

Research and Development in the Pharmaceutical Industry

whitePaper | April 1, 2021

Every year, the U.S. pharmaceutical industry develops a variety of new drugs that provide valuable medical benefits. Many of those drugs are expensive and contribute to rising health care costs for the private sector and the federal government. Policymakers have considered policies that would lower drug prices and reduce federal drug expenditures. Such policies would probably reduce the industry’s incentive to develop new drugs.

Read More
news image

Winning with biosimilars Opportunities in global markets

whitePaper | March 14, 2022

Over the past several years, biologics have gained significant traction in the pharmaceutical industry, representing more than $150 billion in global sales in 2013. By 2020 they are predicted to generate $290 billion in revenue and comprise 27 percent of the pharmaceutical market.i

Read More
news image

The Use of Real-World Data for Personalized Medicine

whitePaper | June 5, 2022

Although our growing scientific understanding and improvements made in medical technology lead to significant advances in human health and wellbeing, many therapy strategies remain insufficient,

Read More
news image

Pharma 2020: Marketing the future. Which path will you take?

whitePaper | August 8, 2021

If Pharma is to create a new marketing and sales model that is fit for 2020, it will have to begin by analysing its own value chain to identify opportunities for working more closely with healthcare payers and providers. It will, for example, have to collaborate much more closely with payers (be they governments, health insurers, employers or patients) to ensure that it develops medicines which have real social and economic value.

Read More
news image

Paving the way for pharma R&D to use FAIR data

whitePaper | December 16, 2019

The use of FAIR (Findable, Accessible, Interoperable and Reusable) data in drug discovery and development could be transformational. But the pharma industry has been slow to embrace FAIR data — partially because of difficulties in establishing the necessary infrastructure and because of internal culture.

Read More

Spotlight

Nesher Pharmaceuticals (USA) LLC

Nesher Pharmaceuticals (USA) LLC, a generic pharmaceutical manufacturer located in St. Louis, MO, is a subsidiary of Zydus Pharmaceuticals (USA) Inc. Our business is redefining the standards for pharmaceutical performance.

Events